Advertisement

Connective Tissue Disorders in Women

  • Sophia L. Ryan
  • Shamik BhattacharyyaEmail author
  • Mary Angela O’Neal
Chapter

Abstract

Connective tissue disorders describe diseases affecting the fascia and are now understood to encompass both genetic and autoimmune causes. Although the diseases have divergent mechanisms, the term is still commonly used and found in the name of some diseases such as “mixed connective tissue disorder.” Of the genetic disorders such as Marfan syndrome or Loeys-Dietz syndrome, some of the causative genes have been identified and mechanisms well explored. Other disorders such as fibromuscular dysplasia remain important clinically without clearly known genetic mechanisms. Depending on the mode of inheritance, each one of the genetic diseases has different proportion of women affected. Connective tissue disorders with autoimmune etiologies, i.e. autoimmune diseases, are common affecting millions of people within the United States and known to injure most organs in the body ranging from skin to kidney to heart to nervous system.

Keywords

Connective tissue disorders Women Systemic lupus erythematosus Sjogren’s Fibromuscular dysplasia 

References

  1. 1.
    Fairweather D, Rose NR. Women and autoimmune diseases. Emerg Infect Dis. 2004;10(11):2005–11.CrossRefGoogle Scholar
  2. 2.
    Whitacre CC. Sex differences in autoimmune disease. Nat Immunol. 2001;2(9):777–80.CrossRefGoogle Scholar
  3. 3.
    Eidinger D, Garrett TJ. Studies of the regulatory effects of the sex hormones on antibody formation and stem cell differentiation. J Exp Med. 1972;136(5):1098–116.CrossRefGoogle Scholar
  4. 4.
    Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol. 2008;173(3):600–9.CrossRefGoogle Scholar
  5. 5.
    Kim S, Liva SM, Dalal MA, Verity MA, Voskuhl RR. Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. Neurology. 1999;52(6):1230–8.CrossRefGoogle Scholar
  6. 6.
    Langer-Gould A. Sex hormones and multiple sclerosis: another informative failure. Lancet Neurol. 2016;15(1):22–3.CrossRefGoogle Scholar
  7. 7.
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.CrossRefGoogle Scholar
  8. 8.
    D’Cruz DP, Khamashta MA, Hughes GRV. Systemic lupus erythematosus. Lancet. 2007;369(9561):587–96.CrossRefGoogle Scholar
  9. 9.
    Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore). 1968;47(4):337–69.CrossRefGoogle Scholar
  10. 10.
    Unterman A, Nolte JES, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011;41(1):1–11.CrossRefGoogle Scholar
  11. 11.
    Mitsikostas DD, Sfikakis PP, Goadsby PJ. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain J Neurol. 2004;127(Pt 5):1200–9.CrossRefGoogle Scholar
  12. 12.
    Palagini L, Mosca M, Tani C, Gemignani A, Mauri M, Bombardieri S. Depression and systemic lupus erythematosus: a systematic review. Lupus. 2013;22(5):409–16.CrossRefGoogle Scholar
  13. 13.
    al CR et. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000... – PubMed – NCBI [Internet]. [cited 2018 Feb 19]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/14530779.
  14. 14.
    Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43(1):77–95.CrossRefGoogle Scholar
  15. 15.
    Appenzeller S, Cendes F, Costallat LTL. Epileptic seizures in systemic lupus erythematosus. Neurology. 2004;63(10):1808–12.CrossRefGoogle Scholar
  16. 16.
    Brandt JE, Priori R, Valesini G, Fairweather D. Sex differences in Sjögren’s syndrome: a comprehensive review of immune mechanisms. Biol Sex Differ. 2015;6:19.CrossRefGoogle Scholar
  17. 17.
    Bhattacharyya S, Helfgott SM. Neurologic complications of systemic lupus erythematosus, sjögren syndrome, and rheumatoid arthritis. Semin Neurol. 2014;34(4):425–36.CrossRefGoogle Scholar
  18. 18.
    Horvath IF, Szodoray P, Zeher M. Primary Sjögren’s syndrome in men: clinical and immunological characteristic based on a large cohort of Hungarian patients. Clin Rheumatol. 2008;27(12):1479–83.CrossRefGoogle Scholar
  19. 19.
    Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87(4):210–9.CrossRefGoogle Scholar
  20. 20.
    Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of sjögren syndrome. Arch Intern Med. 2004;164(12):1275–84.CrossRefGoogle Scholar
  21. 21.
    Delalande S, de Seze J, Fauchais A-L, Hachulla E, Stojkovic T, Ferriby D, et al. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore). 2004;83(5):280–91.CrossRefGoogle Scholar
  22. 22.
    Chai J, Logigian EL. Neurological manifestations of primary Sjogren’s syndrome. Curr Opin Neurol. 2010;23(5):509–13.CrossRefGoogle Scholar
  23. 23.
    Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, et al. The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain J Neurol. 2005;128(Pt 11):2518–34.CrossRefGoogle Scholar
  24. 24.
    Gupta S, Gupta N. Sjögren syndrome and pregnancy: a literature review. Perm J. 2017;21:16–47.Google Scholar
  25. 25.
    De Carolis S, Salvi S, Botta A, Garofalo S, Garufi C, Ferrazzani S, et al. The impact of primary Sjogren’s syndrome on pregnancy outcome: our series and review of the literature. Autoimmun Rev. 2014;13(2):103–7.CrossRefGoogle Scholar
  26. 26.
    Sharma AM, Kline B. The United States registry for fibromuscular dysplasia: new findings and breaking myths. Tech Vasc Interv Radiol. 2014;17(4):258–63.CrossRefGoogle Scholar
  27. 27.
    Olin JW, Gornik HL, Bacharach JM, Biller J, Fine LJ, Gray BH, et al. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation. 2014;129(9):1048–78.CrossRefGoogle Scholar
  28. 28.
    Plouin P-F, Perdu J, La Batide-Alanore A, Boutouyrie P, Gimenez-Roqueplo A-P, Jeunemaitre X. Fibromuscular dysplasia. Orphanet J Rare Dis. 2007;2:28.CrossRefGoogle Scholar
  29. 29.
    Olin JW, Sealove BA. Diagnosis, management, and future developments of fibromuscular dysplasia. J Vasc Surg. 2011;53(3):826–836.e1.CrossRefGoogle Scholar
  30. 30.
    Rushton AR. The genetics of fibromuscular dysplasia. Arch Intern Med. 1980;140:233–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Sophia L. Ryan
    • 1
    • 2
    • 3
  • Shamik Bhattacharyya
    • 1
    • 3
    Email author
  • Mary Angela O’Neal
    • 1
  1. 1.Department of NeurologyBrigham and Women’s HospitalBostonUSA
  2. 2.Department of NeurologyMassachusetts General HospitalBostonUSA
  3. 3.Harvard Medical SchoolBostonUSA

Personalised recommendations